Octave Presents Data at the CMSC 2022 Annual Meeting Showing its Multiple Sclerosis Disease Activity Biomarker Test Produces Clinical Practice Population Insights
MENLO PARK, Calif.--(BUSINESS WIRE)--Octave, the developer of a fully-integrated precision care solution built to deliver comprehensive insights that bring scientific clarity to multiple sclerosis (MS), announced data focused on the company’s novel MS Disease Activity (MSDA) test. The data was shared in a poster presentation at the Consortium of Multiple...
